Reduced global cooperativity is a common feature underlying the amyloidogenicity of pathogenic lysozyme mutations

Journal of Molecular Biology

Volumn 346, Issue 3, 2005, Pages 773-788

  Dumoulin, Mireille ^a   Canet, Denis ^b,f   Last, Alexander M ^b   Pardon, Els ^c   Archer, David B ^d   Muyldermans, Serge ^c   Wyns, Lode ^c   Matagne, Andre ^e   Robinson, Carol V ^a   Redfield, Christina ^b   Dobson, Christopher M ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e UNIVERSITY OF LIÈGE   (Belgium)

^f Geneva Proteomics Inc   (Switzerland)

Author keywords

Amyloidogenic variants; Camel antibody fragments; Human lysozyme; Hydrogen deuterium exchange; Stabilization

Indexed keywords

AMYLOID; ANTIBODY; LYSOZYME;

ALPHA HELIX; ARTICLE; BIOLOGICAL MONITORING; GENETIC VARIABILITY; MASS SPECTROMETRY; MOLECULAR INTERACTION; MUTATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOGENICITY; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN DOMAIN; REDUCTION; WILD TYPE;

EID: 13844281065     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2004.11.020     Document Type: Article

References (38)

1. C.M. Dobson The structural basis of protein folding and its links with human disease Phil. Trans. Roy. Soc. ser. B 356 2001 133 145
2. D.J. Selkoe Folding proteins in fatal ways Nature 426 2003 900 904
3. M. Sunde, and C.C.F. Blake From the globular to the fibrous state: protein structure and structural conversion in amyloid formation Quart. Rev. Biophys. 31 1998 1 39
4. F. Chiti, P. Webster, N. Taddei, A. Clark, M. Stefani, G. Ramponi, and C.M. Dobson Designing conditions for in vitro formation of amyloid protofilaments and fibrils Proc. Natl Acad. Sci. USA 96 1999 3590 3594
5. C.M. Dobson Protein misfolding, evolution and disease Trends Biochem. Sci. 24 1999 329 332
6. M. Fandrich, M.A. Fletcher, and C.M. Dobson Amyloid fibrils from muscle myoglobin Nature 410 2001 165 166
7. J.I. Guijarro, M. Sunde, J.A. Jones, I.D. Campbell, and C.M. Dobson Amyloid fibril formation by an SH3 domain Proc. Natl Acad. Sci. USA 95 1998 4224 4228
8. D. Schenk Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning Nature Rev. Neurosci. 3 2002 824 828
9. J.C. Sacchettini, and J.W. Kelly Therapeutic strategies for human amyloid diseases Nature Rev. Drug Discov. 1 2002 267 275
10. C.M. Dobson Protein folding and disease: a view from the first Horizon symposium Nature Rev. Drug Discov. 2 2003 154 160
11. M.B. Pepys, P.N. Hawkins, D.R. Booth, D.M. Vigushin, G.A. Tennent, and A.K. Soutar Human lysozyme gene mutations cause hereditary systemic amyloidosis Nature 362 1993 553 557
12. S. Valleix, S. Drunat, J.B. Philit, D. Adoue, J.C. Piette, and D. Droz Hereditary renal amyloidosis caused by a new variant lysozyme W64R in a French family Kidney Int. 61 2002 907 912
13. M. Yazaki, S.A. Farrell, and M.D. Benson A novel lysozyme mutation Phe57Ile associated with hereditary renal amyloidosis Kidney Int. 63 2003 1652 1657
14. J. Funahashi, K. Takano, K. Ogasahara, Y. Yamagata, and K. Yutani The structure, stability, and folding process of amyloidogenic mutant human lysozyme J. Biochem. (Tokyo) 120 1996 1216 1223
15. D.R. Booth, M. Sunde, V. Bellotti, C.V. Robinson, W.L. Hutchinson, and P.E. Fraser Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis Nature 385 1997 787 793
16. D. Canet, M. Sunde, A.M. Last, A. Miranker, A. Spencer, C.V. Robinson, and C.M. Dobson Mechanistic studies of the folding of human lysozyme and the origin of amyloidogenic behavior in its disease-related variants Biochemistry 38 1999 6419 6427
17. L.A. Morozova-Roche, J. Zurdo, A. Spencer, W. Noppe, V. Receveur, and D.B. Archer Amyloid fibril formation and seeding by wild-type human lysozyme and its disease-related mutational variants J. Struct. Biol. 130 2000 339 351
18. A.K. Chamberlain, V. Receveur, A. Spencer, C. Redfield, and C.M. Dobson Characterization of the structure and dynamics of amyloidogenic variants of human lysozyme by NMR spectroscopy Protein Sci. 10 2001 2525 2530
19. K. Takano, J. Funahashi, and K. Yutani The stability and folding process of amyloidogenic mutant human lysozymes Eur. J. Biochem. 268 2001 155 159
20. D. Canet, A.M. Last, P. Tito, M. Sunde, A. Spencer, and D.B. Archer Local cooperativity in the unfolding of an amyloidogenic variant of human lysozyme Nature Struct. Biol. 9 2002 308 315
21. S. Muyldermans Single domain camel antibodies: current status J. Biotechnol. 74 2001 277 302
22. M. Dumoulin, K. Conrath, A. Van Meirhaeghe, F. Meersman, K. Heremans, and L.G. Frenken Single-domain antibody fragments with high conformational stability Protein Sci. 11 2002 500 515
23. S. Hooke, S.J. Eyles, A. Miranker, S.E. Radford, C.V. Robinson, and C.M. Dobson Cooperative elements in protein folding monitored by electrospray ionization mass spectrometry J. Am. Chem. Soc. 117 1995 7548 7549
24. M. Dumoulin, A.M. Last, A. Desmyter, K. Decanniere, D. Canet, and G. Larsson A camelid antibody fragment inhibits the formation of amyloid fibrils by human lysozyme Nature 424 2003 783 788
25. Y. Bai, J.S. Milne, L. Mayne, and S.W. Englander Primary structure effects on peptide group hydrogen exchange Proteins: Struct. Funct. Genet. 17 1993 75 86
26. J.D. Harper, and P.T. Lansbury Jr Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins Annu. Rev. Biochem. 66 1997 385 407
27. S.W. Englander Protein folding intermediates and pathways studied by hydrogen exchange Annu. Rev. Biophys. Biomol. Struct. 29 2000 213 238
28. C.M. Dobson Protein folding and misfolding Nature 426 2003 884 890
29. V.W. DeLaGarza Pharmacologic treatment of Alzheimer's disease: an update Am. Fam. Physician 68 2003 1365 1372
30. F.E. Cohen, and J.W. Kelly Therapeutic approaches to protein-misfolding diseases Nature 426 2003 905 909
31. C.M. Dobson In the footsteps of alchemists Science 304 2004 1259 1262
32. S.D. Hooke, S.E. Radford, and C.M. Dobson The refolding of human lysozyme: a comparison with the structurally homologous hen lysozyme Biochemistry 33 1994 5867 5876
33. E. Frare, P. Polverino de Laureto, J. Zurdo, C.M. Dobson, and A. Fontana A highly amyloidogenic region of hen lysozyme J. Mol. Biol. 340 2004 1153 1165
34. M. Dumoulin, and C.M. Dobson Probing the origins, diagnosis and treatment of amyloid diseases using antibodies Biochimie 86 2004 589 600
35. M. Bouchard, J. Zurdo, E.J. Nettleton, C.M. Dobson, and C.V. Robinson Formation of insulin amyloid fibrils followed by FTIR simultaneously with CD and electron microscopy Protein Sci. 9 2000 1960 1967
36. A. Spencer, L.A. Morozov-Roche, W. Noppe, D.A. MacKenzie, D.J. Jeenes, and M. Joniau Expression, purification, and characterization of the recombinant calcium-binding equine lysozyme secreted by the filamentous fungus Aspergillus niger: comparisons with the production of hen and human lysozymes Protein Expr. Purif. 16 1999 171 180
37. Woodruff, N. D. (1998). Investigation of protein structure and folding by NMR spectroscopy. PhD thesis, University of Oxford.
38. R. Koradi, M. Billeter, and K. Wuthrich MOLMOL: a program for display and analysis of macromolecular structures J. Mol. Graph. 14 1996 29 32